Drugs

CURE ID Automating Data Collection

CDER Office of Medical Policy health science policy analyst Heather Stone says the Office of Medical Policy Clinical Methodologies Group (ClinMeth) has made the CURE ID app more effective during the Covid-19 public health emergency. CURE ID allows healthcare providers to report new uses of existing drugs for 325 difficult-to-treat infectious diseases through a standardized simple case report form (CRF) from a Web site or mobile device.

In an online post, Stone says ClinMeth created a user-friendly CRF tailored to Covid-19 and included information on almost all clinical trials submitted to ClinicalTrials.gov for Covid-19 drugs, biologics, and vaccines as well as relevant journal articles, news articles and events, updating the information nearly daily.

“With so many healthcare specialists working on Covid-19,” Stone writes, “the ability to systematically capture and learn from other providers’ treatment experiences is invaluable.”

ClinMeth received a $9.2 million HHS grant 3/2021 to allow it to work with partners over the next two years to expand the open-access CURE ID platform of case reports to include anonymized electronic health record and registry data.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome